Drug intelligence / Profile preview

Luolining

Development stage: Unknown
Lead developer: Nanjing Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

**Luolining** is an oral investigational traditional Chinese medicine capsule developed by Nanjing Zhongshan Hospital for **lymph node tuberculosis**. It was evaluated in China in a randomized, double-blind, placebo-controlled Phase 2 study enrolling patients with the traditional Chinese medicine pattern described as liver qi stagnation and phlegm coagulation. Publicly available records do not clearly identify its individual herbal constituents or a molecular mechanism of action.

Other names: Luolining Capsule

Beyond the preview

Go deeper on Luolining.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luolining.

Explore the full profile